sorafenib has been researched along with tretinoin in 12 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (tretinoin) | Trials (tretinoin) | Recent Studies (post-2010) (tretinoin) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 23,654 | 1,083 | 6,085 |
| Protein | Taxonomy | sorafenib (IC50) | tretinoin (IC50) |
|---|---|---|---|
| Bile salt export pump | Homo sapiens (human) | 10 | |
| Amyloid-beta precursor protein | Homo sapiens (human) | 0.18 | |
| Adenosine receptor A3 | Homo sapiens (human) | 5.275 | |
| Retinoic acid receptor alpha | Homo sapiens (human) | 2.2542 | |
| 60 kDa heat shock protein, mitochondrial | Homo sapiens (human) | 5.3 | |
| Retinoic acid receptor beta | Homo sapiens (human) | 0.7537 | |
| Retinoic acid receptor alpha | Mus musculus (house mouse) | 0.0057 | |
| Retinoic acid receptor gamma | Homo sapiens (human) | 0.0064 | |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 5.275 | |
| Retinoic acid receptor gamma | Mus musculus (house mouse) | 0.004 | |
| Retinoic acid receptor beta | Mus musculus (house mouse) | 0.005 | |
| Mitogen-activated protein kinase 1 | Homo sapiens (human) | 0.576 | |
| Nuclear receptor ROR-alpha | Homo sapiens (human) | 0.1995 | |
| Alpha-synuclein | Homo sapiens (human) | 3 | |
| Cellular retinoic acid-binding protein 1 | Gallus gallus (chicken) | 0.5233 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.358 | |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | 5.275 | |
| Retinoic acid receptor RXR-gamma | Homo sapiens (human) | 0.35 | |
| Nuclear receptor ROR-gamma | Homo sapiens (human) | 0.1995 | |
| 10 kDa heat shock protein, mitochondrial | Homo sapiens (human) | 5.3 | |
| Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 | Homo sapiens (human) | 0.82 | |
| 60 kDa chaperonin | Escherichia coli | 6.7 | |
| 10 kDa chaperonin | Escherichia coli | 6.7 | |
| Nuclear receptor ROR-beta | Homo sapiens (human) | 0.1259 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (8.33) | 29.6817 |
| 2010's | 9 (75.00) | 24.3611 |
| 2020's | 2 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Evans, TR; Roxburgh, P | 1 |
| Açmaz, G; Akkar, OB; Atilgan, R; Boztosun, A; Kosar, MI; Ozer, H | 1 |
| He, XD; Liu, H; Qin, SK; Tao, L; Tong, XH; Wang, ZS; Wu, Q; Yang, Y; Zheng, RS | 1 |
| Delabesse, E; Guenounou, S; Récher, C | 1 |
| Ishijima, N; Kanki, K; Shimizu, H; Shiota, G | 1 |
| Gabrilove, J; Jing, Y; Wang, R; Waxman, S; Xia, L | 1 |
| Aplan, PD; Bruner, JK; Duffield, AS; Ghiaur, G; Greenblatt, SM; Jones, RJ; Jung, E; Li, L; Ma, HS; Nguyen, B; Shirley, CM; Small, D | 1 |
| Bo, LS; Ke, WB; Li, T; Meng, YP; Zhang, Y | 1 |
| Heo, J; Kim, AR; Kim, S; Lee, M; Lee, SY; Seo, HR; Shum, D; Song, Y | 1 |
| Gao, F; He, H; Li, W; Lian, Z; Qiu, X; Su, R; Tan, Y; Wang, K; Xu, H; Xu, X; Zhang, Z; Zhuo, J | 1 |
2 review(s) available for sorafenib and tretinoin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Systemic therapy of hepatocellular carcinoma: are we making progress?
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Estrogens; Humans; Injections, Intravenous; Interferons; Liver Neoplasms; Niacinamide; Palliative Care; Phenylurea Compounds; Pyridines; Risk Factors; Sorafenib; Tretinoin | 2008 |
10 other study(ies) available for sorafenib and tretinoin
| Article | Year |
|---|---|
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
The efficacy of bevacizumab, sorafenib, and retinoic acid on rat endometriosis model.
Topics: Administration, Oral; Animals; Antibodies, Monoclonal, Humanized; Bevacizumab; Disease Models, Animal; Endometriosis; Female; Microvessels; Niacinamide; Phenylurea Compounds; Random Allocation; Rats; Rats, Wistar; Sorafenib; Treatment Outcome; Tretinoin | 2013 |
Connexin-dependent gap junction enhancement is involved in the synergistic effect of sorafenib and all-trans retinoic acid on HCC growth inhibition.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Communication; Cell Line, Tumor; Cell Proliferation; Connexins; Drug Synergism; Gap Junctions; Glycyrrhetinic Acid; Hep G2 Cells; Humans; Liver Neoplasms; Niacinamide; Oleic Acids; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Tretinoin | 2014 |
Sorafenib plus all-trans retinoic acid for AML patients with FLT3-ITD and NPM1 mutations.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Fatal Outcome; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Niacinamide; Nuclear Proteins; Nucleophosmin; Phenylurea Compounds; Sorafenib; Treatment Outcome; Tretinoin; Young Adult | 2014 |
Activation of AMP-activated protein kinase by retinoic acid sensitizes hepatocellular carcinoma cells to apoptosis induced by sorafenib.
Topics: Adenosine Triphosphate; AMP-Activated Protein Kinases; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; Benzoates; Carcinoma, Hepatocellular; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Glucose Transporter Type 1; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Retinoids; Sorafenib; Tetrahydronaphthalenes; Tretinoin | 2015 |
Sorafenib Inhibition of Mcl-1 Accelerates ATRA-Induced Apoptosis in Differentiation-Responsive AML Cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Differentiation; Gene Expression Regulation, Neoplastic; Glycogen Synthase Kinase 3 beta; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-bcl-2; RNA, Small Interfering; Sorafenib; Tretinoin; Xenograft Model Antitumor Assays | 2016 |
All-trans retinoic acid synergizes with FLT3 inhibition to eliminate FLT3/ITD+ leukemia stem cells in vitro and in vivo.
Topics: Animals; Cell Death; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; fms-Like Tyrosine Kinase 3; Gene Duplication; Humans; Leukemia, Myeloid, Acute; Mice; Mutant Proteins; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Tandem Repeat Sequences; Tretinoin; Xenograft Model Antitumor Assays | 2016 |
miR-542-3p Appended Sorafenib/All-trans Retinoic Acid (ATRA)-Loaded Lipid Nanoparticles to Enhance the Anticancer Efficacy in Gastric Cancers.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Humans; Mice, Nude; MicroRNAs; Nanoparticles; Niacinamide; Phenylurea Compounds; Sorafenib; Stomach Neoplasms; Tretinoin | 2017 |
Identification of hepatic fibrosis inhibitors through morphometry analysis of a hepatic multicellular spheroids model.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Colforsin; Drug Synergism; Epithelial-Mesenchymal Transition; Fibroblasts; Hep G2 Cells; Hepatic Stellate Cells; Human Umbilical Vein Endothelial Cells; Humans; Liver Cirrhosis; Liver Neoplasms; Small Molecule Libraries; Sorafenib; Spheroids, Cellular; Tretinoin; Tumor Microenvironment | 2021 |
ATRA sensitized the response of hepatocellular carcinoma to Sorafenib by downregulation of p21-activated kinase 1.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; p21-Activated Kinases; Sorafenib; Tretinoin | 2023 |